Shanghai Shyndec Pharmaceutical Co Ltd - Asset Resilience Ratio
Shanghai Shyndec Pharmaceutical Co Ltd (600420) has an Asset Resilience Ratio of 8.99% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Shanghai Shyndec Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Shanghai Shyndec Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Shyndec Pharmaceutical Co Ltd (600420) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Shyndec Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanghai Shyndec Pharmaceutical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.77 Billion | 8.99% |
| Total Liquid Assets | CN¥1.77 Billion | 8.99% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Shyndec Pharmaceutical Co Ltd maintains only 8.99% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Shyndec Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Shyndec Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Shanghai Shyndec Pharmaceutical Co Ltd (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Shyndec Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.17% | CN¥1.43 Billion ≈ $209.41 Million |
CN¥19.96 Billion ≈ $2.92 Billion |
+6.97pp |
| 2018-12-31 | 0.20% | CN¥33.00 Million ≈ $4.83 Million |
CN¥16.46 Billion ≈ $2.41 Billion |
+0.07pp |
| 2017-12-31 | 0.13% | CN¥20.00 Million ≈ $2.93 Million |
CN¥15.17 Billion ≈ $2.22 Billion |
-0.40pp |
| 2016-12-31 | 0.53% | CN¥80.00 Million ≈ $11.71 Million |
CN¥15.02 Billion ≈ $2.20 Billion |
+0.29pp |
| 2015-12-31 | 0.24% | CN¥10.00 Million ≈ $1.46 Million |
CN¥4.14 Billion ≈ $605.43 Million |
+0.19pp |
| 2007-12-31 | 0.05% | CN¥371.52K ≈ $54.37K |
CN¥713.86 Million ≈ $104.46 Million |
-0.04pp |
| 2004-12-31 | 0.09% | CN¥470.44K ≈ $68.84K |
CN¥516.19 Million ≈ $75.54 Million |
-- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more